Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1
Authors:
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Physiology & Behavior
- Vol. 188, 108-118
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- The promising effect of linagliptin and/or indole-3-carbinol on experimentally-induced polycystic ovarian syndromeChemico-Biological Interactions, 2017
- l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Synapse, 2016
- Nrf2: a modulator of Parkinson’s disease?Journal of Neural Transmission, 2016
- The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of actionDrug Discovery Today, 2016
- Nrf2—a therapeutic target for the treatment of neurodegenerative diseasesFree Radical Biology and Medicine, 2015
- MDS clinical diagnostic criteria for Parkinson's diseaseMovement Disorders, 2015
- Evaluation of Levodopa and Carbidopa Antioxidant Activity in Normal Human Lymphocytes In Vitro: Implication for Oxidative Stress in Parkinson’s DiseaseNeurotoxicity Research, 2014
- Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes MellitusDiabetes Therapy, 2012
- Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: A comparative study in two mouse strainsBehavioural Brain Research, 2005
- Colorimetric assay of catalaseAnalytical Biochemistry, 1972